Increased serum interleukin‐17 levels in patients with myasthenia gravis

Roche, J; Capablo, J.L.; Larrad, Luis; Gervas-Arruga, Javier; Ara, J.R.; Sanchez, A.; Alarcia, Raquel

doi:10.1002/mus.22070

Cited by 79 publications

(51 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of Th17 cells in the pathogenesis of autoimmune diseases and MG has been indicated in several studies [22,24,25]. Other studies have revealed that numbers of Th17 cells and associated cytokines such as IL-17 are increased in patients with MG and in animal models; this is consistent with our finding [26,27,28,29]. We also found that Th17 cell numbers were significantly decreased when compared to measurements taken 6 months after TE.…”

Section: Discussionsupporting

confidence: 83%

Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis

Hosseini

Robat-Jazi

Shaygannejad

et al. 2017

Neuroimmunomodulation

View full text Add to dashboard Cite

Objective: Myasthenia gravis (MG) is an autoimmune disease mediated by autoantibodies against the neuromuscular junction. The thymus has an important role in the pathogenesis of MG because most patients have thymic pathology, and thymectomy (TE) can reduce the severity of the disease. Methods: In this study, the frequency of Th17 and Tc17 cells was studied in 12 MG patients (pre-TE and 6 months post-TE) and in 12 healthy controls (HC). Results: The frequency of Tc17 cells in the pre-TE patients was significantly higher than in the HC (p < 0.05), and after TE, these cells had significantly decreased compared to before TE (p < 0.05). The frequency of Th17 cells in pre-TE patients was significantly higher than in the HC (p < 0.05), and after TE, these cells had significantly decreased compared to before TE (p < 0.05). Conclusion: Our findings indicated a possible role of Tc17 and Th17 in MG pathogenesis.

show abstract

Section: Discussionsupporting

confidence: 83%

Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis

Hosseini

Robat-Jazi

Shaygannejad

et al. 2017

Neuroimmunomodulation

View full text Add to dashboard Cite

show abstract

“…Experiments with gene-deficient mice indicate that Th17 cells and IL-17 play a crucial role in the pathogenesis of EAMG [23,24]. Moreover, previous studies have shown that serum IL-17 concentrations were higher in MG patients compared with controls and correlated with antiAchR antibody titers [25,26].…”

Section: Discussionmentioning

confidence: 97%

Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis

et al. 2015

View full text Add to dashboard Cite

miR-181c is a newly identified negative regulator of immune cell activation. In this study, we aimed to investigate the expression and functional role of miR-181c in myasthenia gravis (MG). miR-181c showed significant downregulation in peripheral blood mononuclear cells (PBMCs) from MG patients compared with healthy controls, with lower expression in generalized patients than in ocular ones. MG patients also had increased serum IL-7 and IL-17 levels. Additionally, serum IL-7 level presents a positive correlation with the serum IL-17 level. miR-181c levels were negatively correlated with serum levels of IL-7 and IL-17 in either generalized patients or ocular patients. A luciferase reporter assay revealed that miR-181c could directly bind to the 3'-UTR of interleukin-7. Forced expression of miR-181c led to decreased IL-7 and IL-17 release in cultured PBMCs, while depletion of miR-181c increased the secretion of these two proinflammatory cytokines. The results from our study suggested for the first time that miR-181c was able to negatively regulate the production of proinflammatory cytokines IL-7 and IL-17 in MG patients, and it is a novel potential therapeutic target for MG.

show abstract

“…Th17 cells in turn secrete the cytokine IL-17A32, and a recent study found that plasma levels of IL-17A were increased in MG patients and that higher levels of IL-17A correlated with greater severity of the disease34. Furthermore, another study presented evidence that serum levels of IL-17 correlates with the AChR antibody titre35. IL-17C, another member of the IL-17 family, has not previously been linked to MG.…”

Section: Discussionmentioning

confidence: 99%

Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients

Molin

Westerberg

Punga

2017

Sci Rep

View full text Add to dashboard Cite

This study describes specific patterns of elevated inflammatory proteins in clinical subtypes of myasthenia gravis (MG) patients. MG is a chronic, autoimmune neuromuscular disease with antibodies most commonly targeting the acetylcholine receptors (AChRab), which causes fluctuating skeletal muscle fatigue. MG pathophysiology includes a strong component of inflammation, and a large proportion of patients with early onset MG additionally present thymus hyperplasia. Due to the fluctuating nature and heterogeneity of the disease, there is a great need for objective biomarkers as well as novel potential inflammatory targets. We examined the sera of 45 MG patients (40 AChRab seropositive and 5 AChRab seronegative), investigating 92 proteins associated with inflammation. Eleven of the analysed proteins were significantly elevated compared to healthy controls, out of which the three most significant were: matrix metalloproteinase 10 (MMP-10; p = 0.0004), transforming growth factor alpha (TGF-α; p = 0.0017) and extracellular newly identified receptor for advanced glycation end-products binding protein (EN-RAGE) (also known as protein S100-A12; p = 0.0054). Further, levels of MMP-10, C-X-C motif ligand 1 (CXCL1) and brain derived neurotrophic factor (BDNF) differed between early and late onset MG. These novel targets provide valuable additional insight into the systemic inflammatory response in MG.

show abstract

Increased serum interleukin‐17 levels in patients with myasthenia gravis

Cited by 79 publications

References 13 publications

Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis

Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis

Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis

Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients

Contact Info

Product

Resources

About